Company
Crossject SA
Headquarters: Dijon, France
Employees: 85
CEO: Mr. Patrick Alexandre
Market Cap
€146.8 Million
EUR as of July 1, 2023
US$160.2 Million
Top Competitors by Market Capitalization
Industry: Medical Instruments & Supplies
| Company | Market Cap (USD) |
|---|---|
Intuitive Surgical, Inc.
|
$116.08 B |
EssilorLuxottica SA
|
$84.47 B |
|
Becton, Dickinson and Company
|
$73.65 B |
Alcon Inc.
|
$40.22 B |
HOYA Corp
|
$39.96 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
|
UnitedHealth Group
|
$428.70 B |
|
Lilly
|
$417.05 B |
|
Johnson & Johnson
|
$412.24 B |
Novo Nordisk
|
$329.83 B |
|
Merck
|
$275.82 B |
Detailed Description
Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.
Unlock the Power of Financial AI:
Try Disfold AI Free for 7 Days!
Stocks & Indices
Crossject SA has the following listings and related stock indices.
Stock: Euronext: ALCJ wb_incandescent
Stock: FSX: 74C wb_incandescent